Drugs / TQB3474
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04144855 | Nov 2018 → Nov 2020 | — | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQB3474 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04144855 ↗ |
| Action | Inhibit | “This is a kind of heat shock protein (HSP90) inhibitor.” NCT04144855 ↗ |
| Route | Intravenous | “Participants receive TQB3474 injection by intravenous (IV) infusion on Day 1, 8, 15, 22 of each 28 day cycle.” NCT04144855 ↗ |